Reprint: Good laboratory practice: preventing introduction of bias at the bench.
As a research community, we have failed to demonstrate that drugs that show substantial efficacy in animal models of cerebral ischemia can also improve outcome in human stroke. Accumulating evidence suggests that this may be due, at least in part, to problems in the design, conduct and reporting of animal experiments, which create a systematic bias resulting in the overstatement of neuroprotective efficacy. Here, we set out a series of measures to reduce bias in the design, conduct and reporting of animal experiments modeling human stroke.
Macleod
Malcolm R
MR
Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Fisher
Marc
M
O'Collins
Victoria
V
Sena
Emily S
ES
Dirnagl
Ulrich
U
Bath
Philip M W
PM
Buchan
Alistair
A
van der Worp
H Bart
HB
Traystman
Richard J
RJ
Minematsu
Kazuo
K
Donnan
Geoffrey A
GA
Howells
David W
DW
D000818:Animals; D015982:Bias; D035843:Biomedical Research / Q000379:methods / Q000592:standards*; D004195:Disease Models, Animal; D017408:Guidelines as Topic / Q000592:standards*; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology*; D012107:Research Design / Q000592:standards*; D020521:Stroke / Q000188:drug therapy*
D018696:Neuroprotective Agents